Trimetazidine has consistently been shown to be effective in improving the left ventricular ejection fraction (LVEF), reducing the New York Heart Association (NYHA) classification, decreasing the rate of hospitalisation and reducing the recorded brain natriuretic peptide (BNP) in patients with heart failure [22,28,30,32]. The gene discussed is NPPB; the disease is heart failure.